|
EP2902030B1
(en)
|
2010-05-14 |
2016-09-14 |
Dana-Farber Cancer Institute, Inc. |
Thienotriazolodiazepine compounds for treating neoplasia
|
|
WO2011143660A2
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating leukemia
|
|
US9266891B2
(en)
*
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
MX366703B
(es)
|
2013-03-15 |
2019-07-22 |
Incyte Holdings Corp |
Heterociclos tricíclicos como inhibidores de la proteína bet.
|
|
WO2015006193A1
(en)
|
2013-07-08 |
2015-01-15 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
EP3027194A1
(en)
*
|
2013-08-01 |
2016-06-08 |
Oncoethix GmbH |
Pharmaceutical formulation containing thienotriazolodiazepine compounds
|
|
WO2015018522A1
(en)
*
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
|
|
WO2015018520A1
(en)
*
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
|
|
WO2015018523A1
(en)
*
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
A novel bet-brd inhibitor for treatment of solid tumors
|
|
EP3030242A1
(en)
*
|
2013-08-06 |
2016-06-15 |
Oncoethix GmbH |
Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
JP2016538310A
(ja)
*
|
2013-11-27 |
2016-12-08 |
オンコエシックス ゲーエムベーハー |
チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
KR20160115953A
(ko)
|
2014-01-31 |
2016-10-06 |
다나-파버 캔서 인스티튜트 인크. |
디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
|
|
JP2017504651A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体の使用
|
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
|
CN106456653A
(zh)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
高胰岛素血症相关病症的治疗
|
|
SI3674302T1
(sl)
|
2014-04-23 |
2023-07-31 |
Incyte Holdings Corporation |
1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
|
|
WO2015168587A1
(en)
*
|
2014-05-02 |
2015-11-05 |
Oncoethix Sa |
Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds
|
|
JP2017514907A
(ja)
*
|
2014-05-02 |
2017-06-08 |
オンコエシックス ゲーエムベーハー |
チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法
|
|
RU2016146099A
(ru)
*
|
2014-05-02 |
2018-06-05 |
Онкоэтикс Гмбх |
Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений
|
|
MX2016014574A
(es)
*
|
2014-05-08 |
2017-02-23 |
Oncoethix Gmbh |
El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
|
|
WO2015169953A1
(en)
*
|
2014-05-08 |
2015-11-12 |
Oncoethix Gmbh |
Method of treating glioma using thienotriazolodiazepine compounds
|
|
AU2015273032A1
(en)
|
2014-06-13 |
2016-12-15 |
Oncoethix Gmbh |
Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
|
|
US9968620B2
(en)
*
|
2014-08-19 |
2018-05-15 |
Oncoethix Gmbh |
Methods of treating lymphoma using thienotriazolodiazepine compounds
|
|
JP2017529332A
(ja)
*
|
2014-08-28 |
2017-10-05 |
オンコエシックス ゲーエムベーハー |
チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法
|
|
ES2855225T3
(es)
|
2014-09-15 |
2021-09-23 |
Incyte Corp |
Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
|
|
SG11201703414VA
(en)
*
|
2014-10-27 |
2017-05-30 |
Tensha Therapeutics Inc |
Bromodomain inhibitors
|
|
CA2969540C
(en)
|
2014-12-02 |
2023-03-21 |
Ignyta, Inc. |
Combinations for the treatment of neuroblastoma
|
|
US10683305B2
(en)
|
2015-04-27 |
2020-06-16 |
Concert Pharmaceuticals, Inc. |
Deuterated OTX-015
|
|
PE20181287A1
(es)
|
2015-09-11 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
|
HK1256419A1
(zh)
|
2015-09-11 |
2019-09-20 |
达纳-法伯癌症研究所股份有限公司 |
乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
|
|
US20170121347A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
SG10201913450PA
(en)
|
2015-11-25 |
2020-03-30 |
Dana Farber Cancer Inst Inc |
Bivalent bromodomain inhibitors and uses thereof
|
|
WO2017106492A1
(en)
|
2015-12-18 |
2017-06-22 |
Ignyta, Inc. |
Combinations for the treatment of cancer
|
|
WO2017121806A1
(en)
*
|
2016-01-15 |
2017-07-20 |
Sandoz Ag |
Pharmaceutical composition of selexipag
|
|
EP3192502A1
(en)
*
|
2016-01-15 |
2017-07-19 |
Sandoz Ag |
Pharmaceutical composition of selexipag
|
|
CR20190027A
(es)
|
2016-06-20 |
2019-05-16 |
Incyte Corp |
Formas sólidas cristalinas de un inhibidor de bet
|
|
KR102718538B1
(ko)
|
2017-07-19 |
2024-10-21 |
이그니타, 인코포레이티드 |
엔트렉티닙을 포함하는 약학적 조성물
|
|
CN111225662B
(zh)
|
2017-10-17 |
2022-11-22 |
伊尼塔公司 |
药物组合物和剂型
|
|
EP3743067A1
(en)
|
2018-01-25 |
2020-12-02 |
Boehringer Ingelheim International GmbH |
Combination treatment of acute myeloid leukemia
|
|
US20230255964A1
(en)
*
|
2019-09-18 |
2023-08-17 |
Bristol-Myers Squibb Company |
Extended release dosage forms for tyk2 inhibitors
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2022034914A1
(ja)
*
|
2020-08-13 |
2022-02-17 |
カルナバイオサイエンス株式会社 |
易溶性固形製剤およびその製法
|
|
TW202241409A
(zh)
*
|
2020-12-18 |
2022-11-01 |
南韓商大熊製藥股份有限公司 |
包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物
|
|
CN116098870B
(zh)
*
|
2023-04-10 |
2023-07-25 |
上海赛默罗生物科技有限公司 |
α5-GABAA受体调节剂的固体分散体及其制备方法
|